237 related articles for article (PubMed ID: 23576741)
1. Modeling Ewing sarcoma tumors in vitro with 3D scaffolds.
Fong EL; Lamhamedi-Cherradi SE; Burdett E; Ramamoorthy V; Lazar AJ; Kasper FK; Farach-Carson MC; Vishwamitra D; Demicco EG; Menegaz BA; Amin HM; Mikos AG; Ludwig JA
Proc Natl Acad Sci U S A; 2013 Apr; 110(16):6500-5. PubMed ID: 23576741
[TBL] [Abstract][Full Text] [Related]
2. Flow perfusion effects on three-dimensional culture and drug sensitivity of Ewing sarcoma.
Santoro M; Lamhamedi-Cherradi SE; Menegaz BA; Ludwig JA; Mikos AG
Proc Natl Acad Sci U S A; 2015 Aug; 112(33):10304-9. PubMed ID: 26240353
[TBL] [Abstract][Full Text] [Related]
3. 3D Tissue-Engineered Tumor Model for Ewing's Sarcoma That Incorporates Bone-like ECM and Mineralization.
Molina ER; Chim LK; Salazar MC; Koons GL; Menegaz BA; Ruiz-Velasco A; Lamhamedi-Cherradi SE; Vetter AM; Satish T; Cuglievan B; Smoak MM; Scott DW; Ludwig JA; Mikos AG
ACS Biomater Sci Eng; 2020 Jan; 6(1):539-552. PubMed ID: 33463239
[TBL] [Abstract][Full Text] [Related]
4. Activation of Wnt/β-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States.
Pedersen EA; Menon R; Bailey KM; Thomas DG; Van Noord RA; Tran J; Wang H; Qu PP; Hoering A; Fearon ER; Chugh R; Lawlor ER
Cancer Res; 2016 Sep; 76(17):5040-53. PubMed ID: 27364557
[TBL] [Abstract][Full Text] [Related]
5. Modeling Stroma-Induced Drug Resistance in a Tissue-Engineered Tumor Model of Ewing Sarcoma.
Santoro M; Menegaz BA; Lamhamedi-Cherradi SE; Molina ER; Wu D; Priebe W; Ludwig JA; Mikos AG
Tissue Eng Part A; 2017 Jan; 23(1-2):80-89. PubMed ID: 27923328
[TBL] [Abstract][Full Text] [Related]
6. Enhanced osteogenic activity by MC3T3-E1 pre-osteoblasts on chemically surface-modified poly(ε-caprolactone) 3D-printed scaffolds compared to RGD immobilized scaffolds.
Zamani Y; Mohammadi J; Amoabediny G; Visscher DO; Helder MN; Zandieh-Doulabi B; Klein-Nulend J
Biomed Mater; 2018 Nov; 14(1):015008. PubMed ID: 30421722
[TBL] [Abstract][Full Text] [Related]
7. Gas foaming of electrospun poly(L-lactide-co-caprolactone)/silk fibroin nanofiber scaffolds to promote cellular infiltration and tissue regeneration.
Chen Y; Jia Z; Shafiq M; Xie X; Xiao X; Castro R; Rodrigues J; Wu J; Zhou G; Mo X
Colloids Surf B Biointerfaces; 2021 May; 201():111637. PubMed ID: 33639507
[TBL] [Abstract][Full Text] [Related]
8. Tissue-Engineered Bone Tumor as a Reproducible Human in Vitro Model for Studies of Anticancer Drugs.
Sakolish C; House JS; Chramiec A; Liu Y; Chen Z; Halligan SP; Vunjak-Novakovic G; Rusyn I
Toxicol Sci; 2020 Jan; 173(1):65-76. PubMed ID: 31626302
[TBL] [Abstract][Full Text] [Related]
9. Three-dimensional in vitro tumor models for cancer research and drug evaluation.
Xu X; Farach-Carson MC; Jia X
Biotechnol Adv; 2014 Nov; 32(7):1256-1268. PubMed ID: 25116894
[TBL] [Abstract][Full Text] [Related]
10. Modeling the Tumor Microenvironment and Pathogenic Signaling in Bone Sarcoma.
Molina ER; Chim LK; Barrios S; Ludwig JA; Mikos AG
Tissue Eng Part B Rev; 2020 Jun; 26(3):249-271. PubMed ID: 32057288
[TBL] [Abstract][Full Text] [Related]
11. Polyurethane foam scaffold as in vitro model for breast cancer bone metastasis.
Angeloni V; Contessi N; De Marco C; Bertoldi S; Tanzi MC; Daidone MG; Farè S
Acta Biomater; 2017 Nov; 63():306-316. PubMed ID: 28927931
[TBL] [Abstract][Full Text] [Related]
12. Extruded Bioreactor Perfusion Culture Supports the Chondrogenic Differentiation of Human Mesenchymal Stem/Stromal Cells in 3D Porous Poly(ɛ-Caprolactone) Scaffolds.
Silva JC; Moura CS; Borrecho G; de Matos APA; da Silva CL; Cabral JMS; Bártolo PJ; Linhardt RJ; Ferreira FC
Biotechnol J; 2020 Feb; 15(2):e1900078. PubMed ID: 31560160
[TBL] [Abstract][Full Text] [Related]
13. Carbon nanofiber amalgamated 3D poly-ε-caprolactone scaffold functionalized porous-nanoarchitectures for human meniscal tissue engineering: In vitro and in vivo biocompatibility studies.
Gopinathan J; Pillai MM; Shanthakumari S; Gnanapoongothai S; Dinakar Rai BK; Santosh Sahanand K; Selvakumar R; Bhattacharyya A
Nanomedicine; 2018 Oct; 14(7):2247-2258. PubMed ID: 30081102
[TBL] [Abstract][Full Text] [Related]
14. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.
Lamhamedi-Cherradi SE; Menegaz BA; Ramamoorthy V; Vishwamitra D; Wang Y; Maywald RL; Buford AS; Fokt I; Skora S; Wang J; Naing A; Lazar AJ; Rohren EM; Daw NC; Subbiah V; Benjamin RS; Ratan R; Priebe W; Mikos AG; Amin HM; Ludwig JA
J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27576731
[TBL] [Abstract][Full Text] [Related]
15. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
16. [Effect of vascular endothelial growth factor 165-loaded porous poly (ε-caprolactone) scaffolds on the osteogenic differentiation of adipose-derived stem cells].
Xu W; Lu H; Ye J; Yang W
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2018 Mar; 32(3):270-275. PubMed ID: 29806274
[TBL] [Abstract][Full Text] [Related]
17. Biomechanical regulation of drug sensitivity in an engineered model of human tumor.
Marturano-Kruik A; Villasante A; Yaeger K; Ambati SR; Chramiec A; Raimondi MT; Vunjak-Novakovic G
Biomaterials; 2018 Jan; 150():150-161. PubMed ID: 29040875
[TBL] [Abstract][Full Text] [Related]
18. Anchorage-independent growth of Ewing sarcoma cells under serum-free conditions is not associated with stem-cell like phenotype and function.
Leuchte K; Altvater B; Hoffschlag S; Potratz J; Meltzer J; Clemens D; Luecke A; Hardes J; Dirksen U; Juergens H; Kailayangiri S; Rossig C
Oncol Rep; 2014 Aug; 32(2):845-52. PubMed ID: 24927333
[TBL] [Abstract][Full Text] [Related]
19. Ewing Sarcoma PDX Models.
Surdez D; Landuzzi L; Scotlandi K; Manara MC
Methods Mol Biol; 2021; 2226():223-242. PubMed ID: 33326106
[TBL] [Abstract][Full Text] [Related]
20. Composite electrospun scaffolds for engineering tubular bone grafts.
Ekaputra AK; Zhou Y; Cool SM; Hutmacher DW
Tissue Eng Part A; 2009 Dec; 15(12):3779-88. PubMed ID: 19527183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
